• Grazoprevir/Elbasvir: Redefining HCV Genotype 1 & 4 Therapy

  2026-05-27

  This review assesses the clinical impact of the fixed-dose combination of grazoprevir (MK-5172 hydrate) and elbasvir for hepatitis C virus (HCV) infection, especially genotypes 1 and 4. The study highlights the regimen’s high efficacy, broad patient applicability—including coinfection and renal impairment—and advances in tolerability and treatment simplicity.

• VE-822 ATR Inhibitor: Enhancing Chemoradiotherapy in PDAC Mo

  2026-05-27

  VE-822, a highly potent ATR inhibitor, is redefining DNA damage response research and radiosensitization in pancreatic ductal adenocarcinoma (PDAC). This article details robust experimental workflows, practical troubleshooting, and emerging use-cases—especially where iPSC-based platforms guide drug selection in ultrarare contexts.

• VE-822 ATR Inhibitor: Precision Tools for DDR Assay Innovati

  2026-05-26

  Explore how VE-822, a potent ATR inhibitor, is transforming DNA damage response (DDR) assay development and personalized cancer research. This in-depth review reveals advanced methodological insights and practical assay recommendations beyond existing protocol guides.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-05-26

  This study demonstrates that cannabidiol (CBD) robustly reduces both the sensory and emotional components of orofacial inflammatory pain in mice. By elucidating CBD’s mechanisms—namely, the modulation of endocannabinoid and serotonergic pathways—the research provides a mechanistic rationale for targeting FAAH and endocannabinoid signaling in pain and mood disorder models.

• Poly(I:C): Driving Precision in Innate Immunity and Translat

  2026-05-25

  This thought-leadership article explores how Poly(I:C), a synthetic double-stranded RNA analog and potent TLR3 agonist, is redefining the boundaries of immune system activation, dendritic cell maturation, and translational research. Blending mechanistic insights with protocol guidance and a strategic outlook, it guides researchers in leveraging Poly(I:C) for robust interferon induction, disease modeling, and next-generation immunotherapeutics.

• Dovitinib (TKI-258): Applied Workflows for Cancer Research

  2026-05-25

  Dovitinib (TKI-258) empowers advanced cancer research by enabling robust inhibition of key RTKs, optimizing apoptosis induction in challenging models like multiple myeloma and hepatocellular carcinoma. This guide delivers actionable experimental protocols, troubleshooting strategies, and practical insights—bridging recent mechanistic breakthroughs with reliable, reproducible bench workflows.

• Gemcitabine in Cancer Research: Protocols, Workflows & Insig

  2026-05-24

  Gemcitabine’s precision as a DNA synthesis inhibitor makes it a cornerstone for apoptosis and DNA damage response assays in cancer research. This guide translates cutting-edge findings and best practices into actionable protocols, troubleshooting, and strategic applications—empowering researchers to harness Gemcitabine’s full potential with confidence.

• Dacarbazine: Applied Workflows for Antineoplastic Chemothera

  2026-05-23

  Dacarbazine is a cornerstone antineoplastic chemotherapy drug, pivotal for DNA alkylation studies across malignant melanoma, Hodgkin lymphoma, and sarcoma research. This article delivers practical protocols, troubleshooting, and workflow innovations—bridging frontline bench science with data-driven insights for reproducibility and translational impact.

• Optimizing ARCA-Capped mRNA Synthesis: Insights with HyperSc

  2026-05-22

  Discover how the HyperScribe Co-transcription mRNA Synthesis Kit Plus streamlines ARCA capped mRNA synthesis for advanced immunotherapy and functional genomics. This in-depth analysis explores unique technical strategies, scientific rationale, and protocol best practices.

• Rucaparib (AG-014699) in DNA Damage Response: Protocols & In

  2026-05-22

  Rucaparib (AG-014699) is redefining DNA damage response research by enabling precision radiosensitization, especially in PTEN-deficient and ETS fusion-expressing prostate cancer models. This article delivers actionable workflows, troubleshooting guidance, and integrates novel reference findings to maximize its application in advanced cancer biology.

• Improved In Vitro Evaluation of Antineoplastic Drug Response

  2026-05-21

  Schwartz's dissertation introduces a refined approach for distinguishing between proliferation arrest and cell death in cancer drug response assays. By delineating relative and fractional viability metrics, this work enhances the mechanistic resolution and reliability of in vitro antineoplastic drug testing, with implications for more predictive translational oncology workflows.

• VE-822 ATR Inhibitor: Transforming Radiosensitization Protoc

  2026-05-21

  VE-822 is redefining the landscape of cancer chemoradiotherapy research by enabling selective, potent inhibition of ATR and enhancing tumor sensitivity to DNA-damaging agents. This guide delivers hands-on protocol refinements, troubleshooting insight, and comparative perspectives, positioning VE-822 as the gold-standard ATR inhibitor for translational DNA damage response studies.

• Cy5 NHS ester(Et): Technical Guidance for Biomolecule Labeli

  2026-05-20

  Cy5 NHS ester(Et) addresses the need for precise, water-soluble fluorescent labeling of primary amines in proteins and other biomolecules, especially in workflows such as immunofluorescence staining, flow cytometry, and fluorescence microscopy. It is not suitable for ethanol-based protocols or long-term storage of working solutions, and requires adherence to strict dissolution and handling parameters to maintain labeling efficiency.

• Cabozantinib XL184: Applied Phosphoproteomic Workflows in RC

  2026-05-20

  Cabozantinib (XL184) delivers potent, multi-kinase inhibition for dissecting signaling adaptation in renal cell carcinoma. Learn how timescale-dependent workflows, advanced phosphoproteomics, and practical troubleshooting elevate experimental rigor and reproducibility in RCC research.

• Crystallization of DDX3 RNA Helicase: Spermine Tetrahydrochl

  2026-05-19

  This study reports the first expression, purification, and crystallization of the human DDX3 RNA helicase domain, with spermine tetrahydrochloride as a critical additive. The resulting high-quality crystals enabled preliminary X-ray analysis, advancing the structural understanding of a protein implicated in RNA metabolism and human disease.

15140 records 1/1010 page Next 12345 下5页 Last page